DRUG
Price
$64.72
Change
+$1.23 (+1.94%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
656.8M
Intraday BUY SELL Signals
RANI
Price
$0.77
Change
-$0.00 (-0.00%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
84.85M
44 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DRUG vs RANI

DRUG vs RANI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DRUG vs. RANI commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a Hold and RANI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 24, 2026
Stock price -- (DRUG: $63.58 vs. RANI: $0.77)
Brand notoriety: DRUG and RANI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DRUG: 104% vs. RANI: 66%
Market capitalization -- DRUG: $618.35M vs. RANI: $86.99M
DRUG [@Biotechnology] is valued at $618.35M. RANI’s [@Biotechnology] market capitalization is $86.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DRUG’s FA Score shows that 1 FA rating(s) are green whileRANI’s FA Score has 1 green FA rating(s).

  • DRUG’s FA Score: 1 green, 4 red.
  • RANI’s FA Score: 1 green, 4 red.
According to our system of comparison, DRUG is a better buy in the long-term than RANI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DRUG’s TA Score shows that 4 TA indicator(s) are bullish while RANI’s TA Score has 2 bullish TA indicator(s).

  • DRUG’s TA Score: 4 bullish, 6 bearish.
  • RANI’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, DRUG is a better buy in the short-term than RANI.

Price Growth

DRUG (@Biotechnology) experienced а +7.45% price change this week, while RANI (@Biotechnology) price change was +0.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

Reported Earning Dates

RANI is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DRUG($657M) has a higher market cap than RANI($84.9M). DRUG YTD gains are higher at: -18.529 vs. RANI (-42.667). DRUG has higher annual earnings (EBITDA): -31.11M vs. RANI (-33.38M). DRUG has more cash in the bank: 310M vs. RANI (43.4M). DRUG has less debt than RANI: DRUG (82.1K) vs RANI (3.94M). RANI has higher revenues than DRUG: RANI (3.17M) vs DRUG (0).
DRUGRANIDRUG / RANI
Capitalization657M84.9M774%
EBITDA-31.11M-33.38M93%
Gain YTD-18.529-42.66743%
P/E RatioN/AN/A-
Revenue03.17M-
Total Cash310M43.4M714%
Total Debt82.1K3.94M2%
TECHNICAL ANALYSIS
Technical Analysis
DRUGRANI
RSI
ODDS (%)
Bullish Trend 2 days ago
68%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 6 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 14 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DRUG
Daily Signal:
Gain/Loss:
RANI
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EPLKX24.150.10
+0.42%
NYLI Epoch U.S. Equity Yield Class C
TRIEX31.61N/A
N/A
Nuveen International Eq Idx Retire
ABFAX12.02N/A
N/A
American Beacon Balanced A
HFYCX15.98N/A
N/A
Hartford Schroders Intl Multi-Cp Val C
GSRFX13.08N/A
N/A
Goldman Sachs Rising Dividend Gr R6

DRUG and

Correlation & Price change

A.I.dvisor indicates that over the last year, DRUG has been loosely correlated with BIVI. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DRUG jumps, then BIVI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DRUG
1D Price
Change %
DRUG100%
+4.81%
BIVI - DRUG
39%
Loosely correlated
+9.94%
BEAM - DRUG
36%
Loosely correlated
+4.07%
RGNX - DRUG
34%
Loosely correlated
+16.22%
PSTV - DRUG
33%
Poorly correlated
-5.83%
CMND - DRUG
32%
Poorly correlated
-2.93%
More

RANI and

Correlation & Price change

A.I.dvisor indicates that over the last year, RANI has been loosely correlated with ARTV. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RANI jumps, then ARTV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RANI
1D Price
Change %
RANI100%
-1.07%
ARTV - RANI
45%
Loosely correlated
-4.68%
IRON - RANI
37%
Loosely correlated
-0.13%
ACHV - RANI
35%
Loosely correlated
+5.05%
VYGR - RANI
32%
Poorly correlated
N/A
DRUG - RANI
31%
Poorly correlated
+4.81%
More